{"disease":{"id":"clostridium-difficile-infection-recurrence","name":"clostridium difficile infection recurrence"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07261826","title":"Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Chen QiYi","has_results":false},{"nct_id":"NCT03562741","title":"Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Krunal Patel","has_results":false},{"nct_id":"NCT03110133","title":"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"Finch Research and Development LLC.","has_results":true},{"nct_id":"NCT04317963","title":"Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT04415918","title":"Bezlotoxumab Efficacy and Tolerability in Cancer Patient","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"The Cooper Health System","has_results":false},{"nct_id":"NCT03788434","title":"Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Vedanta Biosciences, Inc.","has_results":true},{"nct_id":"NCT05831189","title":"A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Ferring Pharmaceuticals","has_results":false},{"nct_id":"NCT04891965","title":"A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Adiso Therapeutics","has_results":false},{"nct_id":"NCT04000555","title":"Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":26,"lead_sponsor_name":"University of South Florida","has_results":false},{"nct_id":"NCT07513285","title":"ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Acurx Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03065374","title":"Treatment for Clostridium-difficile Infection With IMM529","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Immuron Ltd.","has_results":false},{"nct_id":"NCT03880539","title":"Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT03617445","title":"Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}